
Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.